Your session is about to expire
← Back to Search
FES PET/CT Imaging for Breast Cancer
Study Summary
This trial suggests that a new imaging technique, FES PET/CT, may be better at detecting breast cancer metastases than the current standard of care.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- If you are taking certain medications like tamoxifen or fulvestrant, you need to stop taking them for a specific amount of time before having a certain test called FES PET/CT.You weigh over 450 pounds and cannot have a PET/CT scan.You are able to perform daily activities without help or with a little help.You have breast cancer that has been confirmed to be sensitive to estrogen.For cohort 1: You have locally advanced cancer and need a scan to see if it has spread. For cohort 2: You might have cancer come back and need a scan to check.
- Group 1: Suspected disease recurrence
- Group 2: Initial Staging
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the sample size of this research endeavor?
"Indeed, the clinical trial is open for enrolment. The study was initially posted on January 15th 2021 and has undergone a recent update as of January 5th 2022. It aims to recruit 124 people across one medical centre."
Is there an open call for participants in this clinical experiment?
"That is correct. According to the details published on clinicaltrials.gov, this medical research project - which was originally announced on 15th January 2021 - is actively recruiting participants. 124 people are required for 1 site at present time."
Does the FDA officially sanction 18F-fluoroestradiol PET/CT scanning?
"Our team at Power has determined that 18F-fluoroestradiol PET/CT is relatively safe, earning it a score of 2. This rating denotes the presence of safety data but no efficacy evidence due to this being an early phase two trial."
Share this study with friends
Copy Link
Messenger